- Conditions
- Breast Cancer, Hot Flashes, Hot Flushes
- Interventions
- soy protein, isoflavones, Tamoxifen, Placebo
- Dietary Supplement · Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 14
- States / cities
- Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 545
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypotension on Induction
- Interventions
- CirQPOD, Standard airway management
- Device
- Lead sponsor
- Zoll Medical Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab, Pertuzumab, Paclitaxel, Doxorubicin, Cyclophosphamide, Mastectomy, Radiation Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan
- Conditions
- Obstructive Sleep Apnea
- Interventions
- AD036 Dose 1, AD036 Dose 2, AD036 Dose 3, Placebo
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 12
- States / cities
- Glendale, Arizona • Little Rock, Arkansas • Redwood City, California + 9 more
- Conditions
- Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Carcinoma, Squamous Cell, Advanced Solid Tumors
- Interventions
- TAK-659, Nivolumab
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 9
- States / cities
- La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 6 more
- Conditions
- 714leukemia, Lymphoma
- Interventions
- Bortezomib, Everolimus
- Drug
- Lead sponsor
- Brian Hill, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Prostatic Neoplasms
- Interventions
- Pembrolizumab, SD-101, Leuprolide acetate, Abiraterone Acetate, Prednisone, Stereotactic Body Radiation Therapy
- Drug · Radiation
- Lead sponsor
- David Oh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Type 2 Diabetes, Obesity
- Interventions
- Very Low Calorie Diet
- Other
- Lead sponsor
- Durham VA Medical Center
- Federal
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Metastatic Colon Cancer, Solid Tumor
- Interventions
- pembrolizumab, Poly-ICLC
- Drug
- Lead sponsor
- Asha Nayak
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Atezolizumab, Daratumumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 16
- States / cities
- Loma Linda, California • Whittier, California • Newark, Delaware + 13 more
- Conditions
- Epithelial Carcinoma, Solid Tumor
- Interventions
- SYN125, SYN004
- Biological
- Lead sponsor
- Synermore Biologics Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Fairway, Kansas • Brownstown, Michigan • St Louis, Missouri + 1 more
- Conditions
- Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration
- Procedure · Dietary Supplement · Biological + 1 more
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Acute Myeloid Leukemia
- Interventions
- SAR443579, venetoclax, azacitidine
- Biological · Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Duarte, California • The Bronx, New York • Columbus, Ohio + 2 more
- Conditions
- Breast Cancer
- Interventions
- Gemcitabine and Carboplatin, P276-00 along with Gemcitabine and carboplatin
- Drug
- Lead sponsor
- Piramal Enterprises Limited
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Burbank, California • La Jolla, California • Sacramento, California + 1 more
- Conditions
- Pancreatic Cancer
- Interventions
- Walking Program
- Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- 3rd Line GIST
- Interventions
- STI571, BKM120
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Seattle, Washington
- Conditions
- Lung Cancer
- Interventions
- Stereotactic Ablative Radiation Therapy (SABR)
- Radiation
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
- Interventions
- PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI, FOLFOX, Gemcitabine, Mirvetuximab Soravtansine, Trastuzumab Deruxtecan
- Biological · Drug
- Lead sponsor
- Pheast Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Cystinosis
- Interventions
- Cystagon® (Cysteamine Bitartrate), Cysteamine Bitartrate Delayed-release Capsules (RP103)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Stanford, California • Atlanta, Georgia • Chicago, Illinois
- Conditions
- Healthy Volunteers, Speech
- Interventions
- Altered Auditory Feedback (AAF), Visual-Acoustic Biofeedback
- Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sleep Disorder, Blindness
- Interventions
- Melatonin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 5 Years to 20 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- CDX-1401, MPDL3280A
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Solid Tumor, Cancer, Carcinoma
- Interventions
- KHK2455, Mogamulizumab
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Albuquerque, New Mexico • Houston, Texas
- Conditions
- Solid Tumor, Adult
- Interventions
- CF33-CD19 IT Monotherapy, CF33-CD19 IV Monotherapy, CF33-CD19 IT Combination, CF33-CD19 IV Combination, Blinatumomab, Hydroxyurea
- Biological · Drug
- Lead sponsor
- Imugene Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more